Background: Dysregulation of the specialized lipid metabolism involved in myelin synthesis and maintenance by oligodendrocytes has been associated with the unique neuropathology of MSA. We hypothesized that apolipoprotein E, which is associated with neurodegeneration, may also play a role in the pathogenesis of MSA. Objective: This study evaluated genetic associations of Apolipoprotein E alleles with risk of MSA and asynuclein pathology, and also examined whether apolipoprotein E isoforms differentially affect a-synuclein uptake in a oligodendrocyte cell. Methods: One hundred sixty-eight pathologically confirmed MSA patients, 89 clinically diagnosed MSA patients, and 1,277 control subjects were genotyped
for Apolipoprotein E. Human oligodendrocyte cell lines were incubated with a-synuclein and recombinant human apolipoprotein E, with internalized a-synuclein imaged by confocal microscopy and cells analyzed by flow cytometry. Results: No significant association with risk of MSA or was observed for either Apolipoprotein E E2 or E4. aSynuclein burden was also not associated with Apolipoprotein E alleles in the pathologically confirmed patients. Interestingly, in our cell assays, apolipoprotein E E4 significantly reduced a-synuclein uptake in the oligodendrocytic cell line. Conclusions: Despite differential effects of apolipoprotein E isoforms on a-synuclein uptake in a human oligodendrocytic cell, we did not observe a significant association at the Apolipoprotein E locus with risk of MSA or a-synuclein pathology. V C 2018 International Parkinson and Movement Disorder Society Key Words: multiple system atrophy; apolipoprotein E; genetics; protection; oligodendrocyte Widespread presence of glial cytoplasmic inclusions (GCIs) is the neuropathological hallmark of MSA. 1 GCI is the accumulation of a-synuclein protein in the cytoplasm of oligodendrocytes, the myelin-producing support cells in the central nervous system. Recently, dysregulation of the specialized lipid metabolism involved in myelin synthesis and maintenance by oligodendrocytes has been associated with the unique neuropathology of MSA.
2 Apolipoprotein E (APOE) is a well-established lipid-metabolism gene. The APOE E4 allele is the major genetic determinant of late-onset Alzheimer's disease (AD) risk and has also been strongly associated the synucleinopathy dementia with Lewy bodies 3 , whereas APOE E2 is known as a protective factor for AD and dementia. 3 Compared to other more common neurodegenerative diseases, little is known about the genetics of MSA; recent reports have nominated variants in several genes (SNCA, MAPT, LRRK2, COQ2, and GBA) as potential risk factors, though validation is needed. 4 We hypothesized that the APOE alleles could play a role in the pathogenesis of MSA. In this study, we first assessed associations of the APOE E4 and E2 alleles with risk of MSA and with a-synuclein burden. We also investigated whether apolipoprotein E (apoE) differentially affected a-synuclein uptake in a human oligodendrocytic cell line in an isoform-dependent manner. 
Patients and Methods

Study Subjects
One hundred sixty-eight pathologically confirmed MSA patients, 5 89 clinically diagnosed MSA patients, 1 and 1,277 controls were included (Supplementary Table 1 ). The pathologically confirmed patients were all available cases obtained from the Mayo Clinic brain bank for neurodegenerative disorders in Jacksonville, Florida, and were diagnosed by a single neuropathologist (D.W.D.). 5 Both clinically diagnosed MSA patients and control subjects were seen at the Mayo Clinic in Jacksonville, Florida (MSA, N 5 54; Controls, N 5 712) and Rochester, Minnesota (MSA, N 5 35; Controls, N 5 565). All controls were neurologically normal and free of a family history of a movement disorder. All subjects were unrelated nonHispanic whites. The primary comparison was between the pathologically confirmed MSA patients and controls. As a secondary comparison, we combined the pathologically confirmed and clinically diagnosed MSA patients for comparison with controls.
Pathological Analysis
Immunohistochemistry for a-synuclein (NACP; Mayo Clinic antibody, Jacksonville, FL) 6 was conducted to establish the neuropathological diagnosis. 5 The burden of a-synuclein in striatopallidal fibers was measured quantitatively as described previously and was available for 130 of the pathologically confirmed MSA patients. 7 Braak neurofibrillary tangles stage (available for 163 patients) and Thal amyloid phase (available for 158 patients) were assigned to each case with thioflavin S fluorescent microscopy. 8, 9 Genetic Analysis Genomic DNA was extracted from peripheral blood monocytes or frozen brain tissue using the standard protocols. Genotyping for APOE alleles (rs429358 C/T and rs7412 C/T) was performed using a custom TaqMan Allelic Discrimination Assay on an ABI 7900HT Fast Real-Time PCR system (Applied Biosystems, Foster City, CA; primer sequences are available upon request).
Statistical Analysis
Associations of presence of the APOE E4 and E2 alleles with risk of MSA were evaluated using logistic regression models that were adjusted for age and sex. Additionally, we also compared the E3/E3 genotype to the E3/E4 genotype to directly assess the effect of E4, and similarly we compared the E3/E3 genotype to the E2/E3 genotype to directly assess the effect of E2. Finally, we utilized Fisher's exact test to perform a general comparison of APOE genotype. ORs, 95% CIs, and P values result from logistic regression models adjusted for age (age at death for pathologically confirmed MSA patients, age at MSA onset for clinically diagnosed MSA patients, and age at blood draw for controls) and sex. a For comparison of the E3/E3 and E3/E4 genotypes, ORs correspond to the E3/E4 genotype, and individuals with APOE genotypes other than E3/E3 or E3/E4 (i.e., E2/E2, E2/E3, E2/E4, and E4/E4) were excluded. For comparison of the E3/E3 and E2/E3 genotypes, ORs correspond to the E2/E3 genotype, and individuals with APOE genotypes other than E3/E3 or E2/E3 (i.e., E2/E2, E2/E4, E3/E4, and E4/E4) were excluded. CI, confidence interval; N/A, not applicable.
O G A K I E T A L
In pathologically confirmed MSA patients, we assessed associations of E4 and E2 with a-synuclein burden in striatopallidal fibers, Braak stage, and Thal phase using linear regression and proportional odds logistic regression models that were adjusted for age at death and sex. Given that statistical tests of association were performed for both APOE E4 and E2, P 0.025 was considered as statistically significant after Bonferroni correction. With 168 pathologically confirmed MSA patients and 1,269 controls included in our primary analysis, we had 80% power at the P 0.025 significance level to detect odds ratios (ORs) of 1.75 (association with E4) and 1.90 (association with E2) in relation to risk of MSA. All statistical analysis was performed using SAS software (SAS Institute Inc., Cary, NC).
Materials
The human oligodendrocytic cell line, MO3.13, was purchased from Cedarlane Labs (Burlington, NC). Recombinant human a-synuclein, HiLyte Fluor 488 labeled, was from Anaspec (Fremont, CA). Recombinant human apoE proteins were from Fitzgerald Industries (Acton, MA).
Flow Cytometry Analysis of a-Synuclein Uptake
The human oligodendrocytic cell line, MO3.13, were cultured and treated with 10 nM of fluorescently labeled recombinant human a-synuclein with or without 50 nM of recombinant human apoE for 18 hours. A total of 10,000 cells were analyzed by FACS Accuri (BD Biosciences, San Jose, CA). Median fluorescence signals in each condition were quantified using CFLOW plus software (BD Biosciences) and analyzed by one-way analysis of variance (ANOVA) with Tukey's post-hoc analysis.
Confocal Analysis of a-Synuclein Uptake by MO3.13
MO3.13 were plated on coverslips and treated with 250 nM of a-synuclein HiLyte 488 and 1.25 lM of apoE for 18 hours. At the end of the treatment, LysoTracker Red (Life Technologies, Carlsbad, CA) was added to label lysosomes. Iimages were acquired using a confocal laser-scanning fluorescence microscope (LSM 510; Carl Zeiss, Jena, Gewrmany).
Results
There was no significant association of APOE E4 or E2 with risk of MSA ( Table 1) or risk of MSA subtypes (Supplementary Tables 2 and 3) . Similarly, when making a general comparison of APOE genotype with controls, no difference was observed for the pathologically confirmed MSA patients (P 5 0.78) or the combined MSA series (P 5 0.47; Supplementary Table 4) . There was no association between a-synuclein burden in the striatopallidal fibers and presence of either APOE E4 (P 5 0.71) or E2 (P 5 0.49). In the pathologically confirmed MSA series, E4 was associated with a significantly higher Thal phase (P < 0.0001), but was not associated with Braak stage (P 5 0.25), whereas E2 was not associated with either outcome after multiple testing adjustment (P 0.047), though nonsignificant trends toward less AD pathology in E2 carriers were noted (Supplementary Table 5 ).
In our cellular assay, the human oligodendrocytic cell line, MO3.13, showed reduced colocalization of fluorescently labeled a-synuclein and lysoTracker when cotreated with recombinant apoE E4 compared to apoE E2, E3, or bovine serum albumin (Fig. 1A) . The flow cytometry analysis further confirmed the significantly reduced internalization of fluorescently labeled a-synuclein by MO3.13 when cotreated with apoE E4 (Fig. 1B,C) .
Discussion
The results of our genetic study showed that neither the APOE E4 nor E2 alleles were notably associated with risk of MSA. These findings are in line with the results of previous small studies (n 5 22; 59; 47; 40; and 12) [10] [11] [12] [13] [14] and no signal at the APOE locus in the recent genomewide association study of 331 pathologically confirmed MSA patients. 15 It also is worth noting that in agreement with these findings, a recent study reported no association between rapid eye movement sleep behavior disorder (which could be a clinical prodromal feature preceding the development of MSA) and risk of MSA. 16 Interestingly, in our oligodendrocytic cellular assays, we showed that the apoE E4 isoform significantly reduced asynuclein uptake, which means that apoE regulates asynuclein uptake in an isoform-dependent manner. The mechanisms underlying this observation remains to be investigated. Notably, oligodendrocytes have little endogenous a-synuclein 17 ; nevertheless, GCIs (the pathological hallmark of MSA) consist of a-synuclein. One possible mechanism is that oligodendrocytes might take up asynuclein from the extracellular environment to make GCIs in the brain of MSA. 17 Based on our results, we could hypothesize that apoE E4 may be a disease progression modifier for MSA by reducing the uptake of a-synuclein by oligodendrocytes. Although the lack of association between E4 and risk of MSA in our genetic association analysis does not initially seem to support this result, it is important to highlight that, although not statistically significant, the direction of the association that we observed was protective (OR 5 0.78), and based on 95% confidence limits, this could plausibly be as low as 0.56; the possibility of a false-negative association is important to consider. Given our functional data, further studies may be warranted to investigate whether APOE allelic variation plays a role in MSA susceptibility or progression.
